biotech

  1. NorFoster

    Celgene's (CELG) future seems to be a big question mark

    Celgene earnings details. A cut in the outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's R&D expenses is not a good sign.

Forum List

Back
Top